AMERSHAM, England--(BUSINESS WIRE)-- Phlexglobal, the specialist provider of innovative Trial Master File (TMF) and electronic Trial Master File (eTMF) expertise, solutions and services to the life sciences industry, announced today that it has been acquired by Bridgepoint Development Capital (‘BDC’).
BDC, with a particular interest in life sciences, acquires companies with strong market positions and earnings growth potential. Phlexglobal are the world-wide acknowledged TMF Experts, providing TMF solutions, from its best of breed eTMF system PhlexEview, to a range of support services. Previously backed by Inflexion, BDC’s greater reach with more access to capital will further support Phlexglobal’s plans to develop technologies, expand its client base across Pharma, Biotech and Contract Research Organizations and extend its global footprint.
Alan Payne, partner at BDC, said: “With the increasing emergence of technology in the TMF market, the company is now well placed to replicate its eminence in the services market to become the eTMF provider of choice and the leading TMF services brand.”
Stella Donoghue, Phlexglobal managing director said “We are very excited about working with BDC. They will bring a renewed energy and are focused on supporting our growth across the business. Our current management team will remain unchanged, continuing with the business to drive that growth.”
Chairman Steve Kent is confident of Phlexglobal’s position in the future of TMF management “Our technology platform is recognized to be a market leading solution and we intend to cement that position by introducing new, and innovative efficient offerings to our customers.”
About Bridgepoint Development Capital
BDC provides funding to businesses headquartered in France, the Nordic region and the UK. BDC has a team of 19 investment professionals wholly dedicated to its investment activity and operating from offices in London, Paris and Stockholm. It is part of Bridgepoint, the international private equity group, which invests in businesses valued between €200 million and €1 billion across Europe.
More information can be found at www.bridgepoint.eu
Phlexglobal is a specialist provider of technology-enabled, Trial Master File (TMF & eTMF) document management solutions and other support services. They offer a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise to deliver a range of flexible, targeted solutions to meet business needs.
More information can be found at http://www.phlexglobal.com